EP1515953A2 - Neue hydrazid- oder hydrazonderivate von hexahydropyridazin-3-carbocyclische säure, kombinatorische bibliotheken, die diese enthalten, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung - Google Patents

Neue hydrazid- oder hydrazonderivate von hexahydropyridazin-3-carbocyclische säure, kombinatorische bibliotheken, die diese enthalten, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung

Info

Publication number
EP1515953A2
EP1515953A2 EP03760021A EP03760021A EP1515953A2 EP 1515953 A2 EP1515953 A2 EP 1515953A2 EP 03760021 A EP03760021 A EP 03760021A EP 03760021 A EP03760021 A EP 03760021A EP 1515953 A2 EP1515953 A2 EP 1515953A2
Authority
EP
European Patent Office
Prior art keywords
group
compound
hydrazone
formula
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03760021A
Other languages
English (en)
French (fr)
Inventor
Neerja Bhatnagar
Pierre Broto
Jean-François Gourvest
Jacques Mauger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of EP1515953A2 publication Critical patent/EP1515953A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Definitions

  • the invention relates to new hydrazide or hydrazone derivatives of hexahydro-pyridazine-3-carboxylic acid, the chemical libraries (or bookshops) the containers, their preparation, their use as medicaments, in particular as inhibitors of cathépsine K., as well as the pharmaceutical compositions containing them.
  • Metabolic enzymes such as proteases or kinases are enzymes widely distributed in the animal kingdom.
  • proteases capable of selectively catalyzing the hydrolysis of polypeptide layers
  • the four main classes can be cited: aspartic protease, serine, cysteine and metallo-protease.
  • aspartic protease mention may in particular be made of HIV-1 protease, renin, plasmepsins, cathépsine D. Mention may in particular be made, as serine protease, of thrombin, factor Xa, elastase, tryptase, "complement of convertases", protease NS3 and hepatitis C.
  • cysteine proteases there are three structurally distinct groups, the papain group and cathepsins, the ICE group (the caspases) and the picorna-viral group (similar to the serine proteases in which the serine is replaced by a cystene).
  • the papain group and cathepsins there are three structurally distinct groups, the papain group and cathepsins, the ICE group (the caspases) and the picorna-viral group (similar to the serine proteases in which the serine is replaced by a cystene).
  • cathépsine K cathépsine B
  • cathépsine L cathépsine S
  • caspases the rhinovirus 3C protease and papains and calpains.
  • metalloprotease there may be mentioned in particular the angiotensin converting enzyme, the neutral endopeptidase and the mixture of the two, the metalloprotease matrix as well as the Tumor-necrosis Factor- ⁇ -Converting Enzyme.
  • kinase or protease enzymes are involved in catabolization and inter and intracellular communication processes: they play an important role in a large number of diseases in different fields such as in particular the cardiovascular field, oncology, the central nervous system, 'inflammation, osteoporosis and also infectious, parasitic, fungal or viral diseases. This is why these proteins are targets of great interest for pharmaceutical research.
  • n is an integer from 0 to 6 inclusive
  • R x represents a group chosen from: C (0) - (CH 2 ) m -R
  • R is one of the groups: hydrogen when m is different from 0; hydroxy or thiol; cyano; linear or branched alkoxy containing from 1 to 6 carbon atoms or aryloxy or aralkoxy; cycloalkyl having 3 to 6 carbon atoms; saturated or unsaturated monocyclic or bicyclic heterocyle group; the nucleus of the heterocyl radical being optionally substituted with one to three substituents chosen from: OH, SH, NH 2 , NO 2 , cyano, carboxy, 5 carbamoyl, halogen, trifluoromethyl, linear or branched alkyl containing from 1 to 6 carbon
  • R 2 identical or different has the same meaning as Ri, or may represent hydrogen
  • n is 2.
  • R 2 represents hydrogen.
  • the lateral group
  • the lateral group
  • the compound has the following stereochemistry:
  • the products of the present invention as defined above and below have inhibitory properties of metabolic enzymes as defined above in particular of kinases or of proteases such as in particular the cysteine proteases or serine proteases.
  • the products of the present invention can thus in particular be useful in the prevention or treatment of diseases in which such metabolic enzymes are involved such as certain cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, bone diseases such as for example osteoporosis, infectious diseases requiring in particular for their therapy anti-infectives or certain cancers.
  • diseases in which such metabolic enzymes are involved such as certain cardiovascular diseases, diseases of the central nervous system, inflammatory diseases, bone diseases such as for example osteoporosis, infectious diseases requiring in particular for their therapy anti-infectives or certain cancers.
  • the bivalent group represented by - (CH 2 ) n - can be linear or branched.
  • aryl containing 6 to 10 carbon atoms denotes an unsaturated radical, comprising one or two fused rings, optionally interrupted by one to three heteroato es chosen from nitrogen, oxygen and sulfur. Mention may be made of: phenyl, naphthyl.
  • aralkyl containing from 7 to 11 carbon atoms denotes an aryl radical as above, linked by a linear or branched alkyl radical, this alkyl radical having from 1 to 5 carbon atoms. Mention may in particular be made of benzyl.
  • alkoxy, ayloxy and aralkyloxy indicate the presence of a terminal oxygen on the alkyl, aryl or aralkyl group.
  • heterocyclic radical denotes a saturated or unsaturated radical consisting of 5 or 6 links such that one or more of the links represents an oxygen, sulfur or nitrogen atom: such a heterocyclic radical thus denotes a carbocyclic radical interrupted by one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms, it being understood that heterocyclic radicals can contain one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms and only when these heterocyclic radicals have more than one heteroatom, the heteroatoms of these heterocyclic radicals may be the same or different.
  • piperazinyl piperazinyl radical substituted by an
  • morpholinyl and thienyl radicals such as 2-thienyl and 3-thienyl and furyl radicals such as 2-furyl, tetrahydrofuryl, thienyl, tetrahydrothienyl, pyrrolyl, pyrrolinyl, pyridyl and pyrrolidinyl.
  • bicyclic heterocyclic radical denotes a saturated or unsaturated radical consisting of 8 to 12 members such that one or more of the members represents an oxygen, sulfur or nitrogen atom and in particular condensed heterocyclic groups containing at least one heteroatom chosen from sulfur, nitrogen and oxygen, for example benzothienyl such as 3-benzothienyl, benzothiazolyl, quinolyl, tetralone, benzofuryl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl or purinyl.
  • benzothienyl such as 3-benzothienyl, benzothiazolyl, quinolyl, tetralone, benzofuryl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl or purinyl.
  • the compounds of formula (1) can be salified by various groups known to those skilled in the art, among which there may be mentioned, for example:
  • mineral bases such as, for example, an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxy-methyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procalne, lysine, arginine, histidine, N-methyl-glucamine,
  • mineral bases such as, for example, an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxy-methyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine
  • the addition salts with mineral or organic acids of the products of formula (1) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids , benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulfonic acids such as for example methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, alkylldisulfonic acids such as for example methanedisulfonic acid, alpha acid , beta-ethanedisulfonic, arylmonosulfonic acids such as benzenesulfonic acid and aryldisulfonic acids.
  • hydrochloric hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propi
  • stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but the different groups of which are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in axial or equatorial position, and the different possible rotational conformations of ethane derivatives.
  • stereoisomerism due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, which is often called geometric isomerism or cis-trans isomerism.
  • stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
  • the present invention thus also relates to chemical libraries (or bookstores).
  • These libraries are in particular in the form of matrices of variable rank, the rank being at least 2, at least 2 rows containing at least 2 compounds, each compound being individualized. It is understood that these matrices can be made available in a form which is not necessarily of the same rank; thus it is possible to obtain a row 3 matrix in the form of plates with test pieces, the plates being of order 2. It is also understood that the matrices, for example of row 3, when they are available in a order form 3 or lower, are not necessarily ordered.
  • the invention also covers the chemical libraries in the form of sets comprising a plurality of compounds according to the invention, each compound being individualized.
  • This set of compounds notably comprises plates with wells each comprising a compound according to the invention.
  • These sets comprise at least 4 individualized compounds according to the invention.
  • the chemical libraries according to the invention are in particular discreet.
  • the chemical libraries generally comprise a large number of compounds, typically of the order of a hundred or a thousand.
  • the compounds are prepared in the form of chemical libraries, as indicated above. It is also possible to prepare them in a conventional manner by implementing the process, compound by compound.
  • the method according to the invention thus comprises the following steps:
  • the reagents used Ri ', R 2 ' and R 3 ' are precursors. They react with amino functions (secondary or primary) to lead to the desired groups.
  • the coupling reaction is carried out conventionally on a resin type support, for example by reductive amination (typically reaction of the primary amine on an aldehyde present on the base resin; the reaction is carried out by adding a suspension of the product II in a dichloromethane / DMF mixture with the resin followed by addition of sodium borohydride triacetate).
  • the resin is a 4-formyl-3,5-dimethoxyphenoxy type resin (PL-FDMP, Polymer Laboratories Stratospheres).
  • the hydrazynolysis reaction is carried out conventionally by adding hydrazine.
  • the cleavage reaction is carried out conventionally by the action of trifluoroacetic acid in dichloromethane (50/50).
  • the process according to the invention can also comprise one or more of the following optional reactions, in an appropriate order, to obtain the desired compound:
  • the reactive functions which it is appropriate, if necessary, to protect are generally the carboxylic acid, amino, amide and hydroxy functions.
  • the protection of the acid function is in particular carried out in the form of alkyl esters, allylic esters, benzyl, benzhydryl or p-nitrobenzyl.
  • Deprotection is carried out by saponification, acid hydrolysis, hydrogenolysis, or even cleavage using soluble complexes of Palladium O.
  • the protection of amines and amides is in particular carried out in the form of benzylated derivatives, in the form of carbamates, in particular of allyl, benzyl, phenyl or tertbutyl, or also in the form of silylated derivatives such as the tertbutyl dimethyl, trimethyl, triphenyl derivatives or else diphenyl tertbutyl-silyl.
  • Deprotection is carried out, depending on the nature of the protective group, by sodium or lithium in liquid ammonia, by hydrogenolysis or using soluble complexes of Palladium O, by the action of an acid, or by the action of fluoride. of tetrabutylammonium.
  • the protection of alcohols is carried out in a conventional manner, in the form of ethers, esters or carbonates.
  • the ethers may be alkyl or alkoxyalkyl ethers, preferably methyl or methoxyethoxymethyl ethers, aryl or preferably aralkyl ethers, for example benzyl, or silylated ethers, for example derivatives silylates cited above.
  • the esters can be any cleavable ester known to a person skilled in the art and preferably acetate, propionate or benzoate or p-nitrobenzoate.
  • the carbonates can be, for example, methyl, tert-butyl, allyl, benzyl or p-nitrobenzyl carbonates.
  • Deprotection is carried out by means known to those skilled in the art, in particular saponification, 1 hydrogenolysis, cleavage by soluble complexes of Palladium O, hydrolysis in an acid medium or, for silylated derivatives, treatment with tetrabutylammmonium fluoride.
  • the amidification reaction is carried out starting from the carboxylic acid using an activating agent such as an alkyl chloroformate or EDCI, by the action of ammonia or an appropriate amine. or their acid salts.
  • the acylation and sulfonylation reactions are carried out on the hydroxyureas by the action respectively of a suitable halide or anhydride of carboxylic acid or a suitable halide of sulfonic acid.
  • the alkylation reaction is carried out by action on the hydroxylated derivatives of an alkyl halide or of substituted alkyl, in particular by a free or esterified carboxy radical.
  • the reduction of acids into alcohols can be carried out by the action of a borane or, via an intermediate mixed anhydride, by the action of an alkaline borohydride.
  • the mixed anhydride is prepared for example using an alkyl chloroformate.
  • Salification with acids is optionally carried out by adding an acid in the soluble phase to the compound.
  • Salification with bases can relate either to compounds comprising an acid function, in particular carboxy, or those comprising a function sulfooxy or those comprising an heterocycle of acidic nature.
  • the procedure is carried out by adding an appropriate base such as those mentioned above.
  • the pyridinium salt is obtained directly during the action of the SO 3 -pyridine complex and the other salts are obtained from this pyridinium salt. In either case, one can still operate by ion exchange on resin. Examples of salifications appear below in the experimental part.
  • IRORI ® technology is used (including the "directed sorting"), steps (ii), (iii) and (v) being randomized with reagents R x ', R 2' and R 3 'available. The individualized products are then then collected in flasks.
  • Salification with acids is optionally carried out by adding an acid in the soluble phase to the compound.
  • Salification with bases can relate either to compounds comprising an acid function, in particular carboxy, or those comprising a function sulfoxy or those comprising an heterocycle of acidic nature.
  • the procedure is carried out by adding an appropriate base such as those mentioned above.
  • the pyridinium salt is obtained directly during the action of the SO 3 -pyridine complex and the other salts are obtained from this pyridinium salt. In either case, it is still possible to operate by ion exchange on resin. Examples of salifications appear below in the experimental part.
  • the products of the present invention can thus be endowed with inhibitory properties of one or more metabolic enzymes as defined above, in particular kinases or proteases.
  • Certain products of formula (I) of the present invention as defined above, can therefore in particular have inhibitory properties of certain protein kinases or proteases.
  • proteases of interest it is possible to target cathepsins B, H, J, L, N, S, T, C, V, K or O, 02; especially those involved in diseases of cartilage and bone metabolism and bone cancer, and especially cathépsine K.
  • the levels, regulation and activity of a certain number of protein kinases or proteases play a role in several human pathologies.
  • the activity of a protein kinase or protease can in particular be associated with receptors having transmembrane domains or with intracellular proteins.
  • Certain kinases or proteases can play a role in the initiation, development and completion of cell cycle events and thus, inhibitory molecules of such kinases or proteases are capable of limiting unwanted cell proliferation such as those observed in cancers, psoriasis, growth of fungi, parasites (animals, protists): such molecules inhibiting these kinases or proteases are thus also likely to intervene in the regulation of neurodegenerative diseases such as Alzheimer's disease.
  • Certain products of formula (I) as defined above may, as kinase or protease inhibitors, have in particular the property of inhibiting bone resorption mediated by osteoclasts. They can therefore be useful for the therapeutic or prophylactic treatment of diseases which are caused at least in partly by an unwanted increase in bone resorption, for example osteoporosis.
  • Certain products of formula (I) of the present invention can thus for example inhibit the enzymatic digestion of the collagen of the bone matrix and thus the bone resorption by the osteoclasts.
  • osteoporosis are in particular osteoporosis, hypercalcemia, osteopenia, for example caused by bone metastases, dental disorders for example periodontitis, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, disease of Paget, osteopenia induced by immobilization.
  • the compounds of formula (I) can be used to relieve, prevent or treat bone disorders which are caused by treatments, by glucocorticoids, therapies linked to the taking of steroids or corticosteroids or by deficiencies. male or female sex hormones.
  • All of these disorders are characterized by bone loss, which is based on a lack of balance between bone formation and bone destruction and which can be favorably influenced by the inhibition of bone resorption by osteoclasts.
  • Certain products of formula (I) of the present invention may have, in addition to their specific inhibitory properties of kinases or proteases, interesting cellular effects such as antiproliferative properties and in particular effects on apoptosis. It is known from the work described in the literature such as in WO 97/20842 that relationships exist between the cell cycle and apoptosis. Among the pathways leading to apoptosis, some are dependent on kinases or proteases.
  • the products of the present invention are particularly useful for the therapy of tumors.
  • the products of the invention can thus also increase the therapeutic effects of commonly used anti-tumor agents.
  • the products of formula (I) of the present invention also have antimitotic and anti-neurodegenerative properties.
  • Certain products of the present invention can be inhibitors of vasoconstrictor and hypertensive effects and thus produce an anti-ischemic effect, or even oppose stimulating effects at the level of certain cellular types in particular smooth muscle cells, fibroblasts, cells. neuronal and bone cells.
  • the products according to the present invention can thus be used in the treatment of diseases such as proliferative diseases, cancer, restenosis, inflammation; allergies, cardiovascular disease or certain infectious diseases.
  • diseases such as proliferative diseases, cancer, restenosis, inflammation; allergies, cardiovascular disease or certain infectious diseases.
  • the products of the present invention can also be used in the treatment of certain gastrointestinal, gynecological disorders and in particular for a relaxing effect on the uterus.
  • the products of formula (I) of the present application can thus have interesting properties pharmacological justifying their application in therapy.
  • the invention therefore also relates to the compounds according to the invention for their use as medicaments, intended for the prevention or treatment of the diseases mentioned above.
  • the invention particularly relates to pharmaceutical compositions containing as active ingredient at least one of the compounds according to the invention in combination with a pharmaceutically acceptable carrier.
  • compositions of the present invention as defined above can be administered by the oral route, by parenteral route or by local route in topical application on the skin and the mucous membranes or by injection by intravenous or intramuscular route.
  • These compositions can be solid or liquid and can be presented in all the pharmaceutical forms commonly used in human medicine such as, for example, simple or coated tablets, pills, tablets, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods.
  • the active ingredient can be incorporated therein into excipients usually used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
  • excipients usually used in these pharmaceutical compositions such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting, dispersing or emulsifying agents, preservatives.
  • the usual dosage which varies according to the product used, the subject treated and the condition in question, can be, for example, from 0.05 to 5 g per day in adults, or preferably from 0.1 to 2 g per day.
  • Another subject of the invention is the use of the compounds according to the invention for the manufacture of medicaments intended for the prevention or treatment of the diseases mentioned above.
  • the backbone of formula II is prepared by synthesis from intermediate hexahydropyridazic-3-carboxylic acid (see also the description as an intermediate product in documents WO-A-9955724,
  • a 4-formyl-3,5-dimethoxyphenoxy-methyl polystyrene resin is used.
  • the resin 25g, 1.5 mmol / g
  • the resin is put to swell in DCM (250ml) then filtered; it is then suspended in 200ml of DCM plus 100ml of DMF.
  • a gas evolution is observed.
  • the mixture is left stirring for 4 hours then the resin is filtered and washed successively with 2X200ml of DMF then 4X following the cycle of 200ml of DCM and 200ml of MeOH, one last washing being carried out with 200 ml of ether. 35 g of grafted resin are obtained. HR Mass analysis is consistent.
  • Acid anhydrides the reagent (2 eq) is added to the DCM and then the DIEA (5 eq). The mixture is stirred at ambient temperature for 4 h and then the resin is washed (same cycle as above).
  • the following reagents are used: acetic anhydride, isovaleric anhydride, 4-methoxybenzoic anhydride.
  • Sulfonyl chlorides the conditions are the same as for (thio) isocyanates.
  • the following reagents are used: thiophene sulfonyl chloride, naphthalene sulfonyl chloride and mesitylene sulfonyl chloride.
  • the 810 MiniKans are placed in 0.6L of DMF and 0.2L of hydrazine monohydrate. The mixture is stirred at ambient temperature for 15 h and then the resin is washed with 2XDMF (0.6L), then 5XDCM / MeOH
  • IL 1XDCM
  • IL lXether
  • the mixture is stirred at room temperature for 3 h and then the resin is washed.
  • the following reagents are used: propane sulfonyl chloride and 2-thiophene sulfonyl chloride.
  • Acid anhydrides the reagent (2 eq) is added to the DCM and then the DIEA (4 eq). The mixture is stirred at ambient temperature for 3 h and then the resin is washed. The following reagent is used: phenoxy acetic anhydride.
  • the kans are sorted into IRORI ® cleavage blocks with the help of the autosortor.
  • the products are cleaved by adding 2 ml of TFA / DCM 50/50 solution.
  • the cleavage solutions are filtered in pre-prepared test tubes and evaporated.
  • Each product is redissolved in 1 ml of acetonitrile, 50 ⁇ l of aliquot of which is taken and transferred to a 96-well plate for LC / MS analysis.
  • the aliquot is diluted in 1 ml of CH 3 CN / H 2 0 solution and directly injected in LC / MS.
  • MiniKans are then dried under vacuum at 40 ° C for 5h.
  • Isocyanates, isothiocyanate the reagent (5 eq) is added to the DCM. The mixture is stirred at ambient temperature for 2 h and then the resin is washed. The following reagents are used: Ethyl isocyanate; 4- (trifluoromethyl) phenyl isocyanate; Cyclopropyl isothiocyanate; Phenyl isocyanate.
  • Carboxylic acids the reagent (3 eq) and 993 mg of HOBt (6 eq, 135.13 g / mol) are added to DMF then 1.15 mL of DIC (6 eq, 126.20 g / mol, 0.806). The mixture is stirred at ambient temperature for 1 night and then the resin is washed.
  • the following reagents are used: 3- (1-cyanoethyl) benzoic acid; benzoic acid; 6-methylpicolinic acid; 3- (2-pyridyl) -acrylic acid; pyrazine carboxylic acid; benzofurazan-5-carboxylic acid; quinaldic acid; trans-2-hexenoic acid.
  • the reagent (5 eq) is added to DCM and then 2.5 mL of DIEA (12 eq, 129.26 g / mol, 0.755). The mixture is stirred at ambient temperature for 4 h and then the resin is washed.
  • the following reagents are used: valeric anhydride; isovalenic anhydride; anhydride 4- methoxybenzoic; methacrylic anhydride; 2-phenylbutyric anhydride; acetic anhydride.
  • Sulfonyl chlorides the reagent (5 eq) is added to the DCM and then 2.1 mL of DIEA (10 eq). The mixture is stirred at ambient temperature for 4 h and then the resin is washed.
  • the following reagents are used: 2-naphthalenesulfonyl chloride; 2-mesitylenesulfonyl chloride; 2-thiophenesulfonyl chloride.
  • Each reactor contains 24 MiniKans in 50 mL of THF / HC (OMe) 3 (l / l). Each aldehyde is added so as to obtain a concentration of 0.5M. The mixture is heated at 60 ° C. for 18 hours and then the resin is washed. The following reagents are used: 3-carboxybenzaldehyde; 3- methoxybenzaldehyde; 6-methoxy-2-naphthaldehyde; 4- nitrocinnamaldehyde; 4-cyanobenzaldehyde; 4- (ethylmercapto) benzaldehyde; 4-
  • the kans are sorted into IRORI ® cleavage blocks with the help of the autosortor.
  • the products are cleaved by adding 2 ml of TFA / DCM 50/50 solution.
  • the cleavage solutions are filtered in pre-prepared test tubes and evaporated.
  • Each product is redissolved in 1 ml of acetonitrile, 50 ⁇ l of aliquot of which is removed and transferred to a 96-well plate for LC / MS analysis.
  • the aliquot is diluted in 1 ml of CH 3 CN / H 2 0 solution and directly injected in LC / MS.
  • the products to be tested (10 mM) are diluted to 1 mM in DMSO and distributed in 96 well Nunc polystyrene plates at a rate of 2 ⁇ l per well. Column 12 of the plate is reserved for controls and therefore receives 1 ⁇ l of DMSO (without products) per well.
  • the plates are stored at -80 ° C. and thawed on the day of the experiment.
  • reaction buffer 100 mM sodium acetate, EDTA 5 mM, 1 mM DTT, pH 5.5.
  • reaction buffer 100 mM sodium acetate, EDTA 5 mM, 1 mM DTT, pH 5.5.
  • the addition as well as all the following pipetting operations are carried out by a 96-cone CybiWell pipetting device. After mixing the solutions, each product is transferred to 2 wells (duplicates) of a 384-well black Greiner plate at the rate of 10 ⁇ l per well. We can therefore test 2 plates 96 in a plate 384.
  • a solution of Cathépsine K at 12.5 ng / ml is prepared in the reaction buffer and distributed to all the wells of the plate 384 (20 ⁇ l per well) except the 16 wells serving as 100% inhibition controls (column 23 and 24, lines I to P) which will receive 20 ⁇ l of buffer without enzyme.
  • the 100% inhibition controls are carried out in columns 23 and 24, lines A to H which do not contain products.
  • the final concentrations of each of the reagents are: Products 10 ⁇ M, Substrate 20 ⁇ M, enzyme 5 ng / ml.
  • The% inhibition for each of the products is calculated using the points at 0 and 100% inhibition of each plate as references. Products with significant inhibition are then retested over a concentration range from 50 to 0.5 ⁇ M to determine an IC50. The results show that the products according to the invention are active.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP03760021A 2002-06-14 2003-06-12 Neue hydrazid- oder hydrazonderivate von hexahydropyridazin-3-carbocyclische säure, kombinatorische bibliotheken, die diese enthalten, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung Withdrawn EP1515953A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0207346A FR2840898B1 (fr) 2002-06-14 2002-06-14 Derives hydrazide ou hydrazone de l'acide hexahydropyridazine-3-carboxylique, chimiotheques et compositions pharmaceutiques les contenant, utilisation comme medicaments, et procede de preparation
FR0207346 2002-06-14
PCT/FR2003/001770 WO2003106431A2 (fr) 2002-06-14 2003-06-12 Nouveaux derives hydrazide ou hydrazone de l'acide hexahydro-pyridazine-3-carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation

Publications (1)

Publication Number Publication Date
EP1515953A2 true EP1515953A2 (de) 2005-03-23

Family

ID=29595243

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03760021A Withdrawn EP1515953A2 (de) 2002-06-14 2003-06-12 Neue hydrazid- oder hydrazonderivate von hexahydropyridazin-3-carbocyclische säure, kombinatorische bibliotheken, die diese enthalten, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung

Country Status (10)

Country Link
US (1) US7279480B2 (de)
EP (1) EP1515953A2 (de)
JP (1) JP2005530823A (de)
AU (1) AU2003260582A1 (de)
BR (1) BR0312127A (de)
CA (1) CA2489447A1 (de)
FR (1) FR2840898B1 (de)
IL (1) IL165731A0 (de)
MX (1) MXPA04010747A (de)
WO (1) WO2003106431A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7725386B2 (en) * 2004-03-15 2010-05-25 Arthur J Prieston Method for offering representation and warranty insurance for mortgage loans
WO2008054633A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Hydrazone derivatives as kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03106431A2 *

Also Published As

Publication number Publication date
US20050215553A1 (en) 2005-09-29
CA2489447A1 (fr) 2003-12-24
FR2840898A1 (fr) 2003-12-19
US7279480B2 (en) 2007-10-09
MXPA04010747A (es) 2005-03-07
WO2003106431A2 (fr) 2003-12-24
FR2840898B1 (fr) 2004-08-27
BR0312127A (pt) 2005-03-29
IL165731A0 (en) 2006-01-15
JP2005530823A (ja) 2005-10-13
WO2003106431A3 (fr) 2004-04-08
AU2003260582A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
EP0526348B1 (de) Indolinderivate mit einer Amidgruppe, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
EP3083564B1 (de) Heteroarylbuttersäurederivate als lta4h-hemmer
FR2609716A1 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments
JP2009242437A (ja) スルホンアミド誘導体
KR101087883B1 (ko) 포유류 아난다미드 운반물질을 억제하는 아민, 및 이의사용 방법
EP1515953A2 (de) Neue hydrazid- oder hydrazonderivate von hexahydropyridazin-3-carbocyclische säure, kombinatorische bibliotheken, die diese enthalten, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
WO2003099812A1 (fr) Derives de phenyl-furane ou de phenyl-thiophene, leur preparation et leur application a titre de medicament
FR2907120A1 (fr) Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
EP1532134B1 (de) Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen
EP1476434B1 (de) Pyridazinderivate, deren verwendung als heilmittel, und deren verfahren zu ihrer verwendung
EP1503991A1 (de) Hexahydropyridazin-3-carbonsäurederivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
EP1246824B1 (de) Diazepinecarboxamidderivate, verfahren zu ihrer herstellung ,ihre verwendung als arzneimittel, pharmazeutische zubereitungen und ihre verwendung
MC2418A1 (fr) Procédé de préparation d'un acide (-) - (3R)-3-méthyl-4-[4-[4- (4-pyridyl) pipérazine-1-yl] phénoxy]butyrique et d'une composition pharmaceutique le contenant
JP2004026837A (ja) ６−アミノ−２，２−ジメチル−３，４，６−トリ置換ベンゾピラン誘導体と固相パラレル合成法を用いたその製造方法
HK1224661A1 (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
HK1224661B (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
FR2734818A1 (fr) Acide (-)-(3r)-3-methyl-4-{4-[4-(4-pyridyl)piperazine-1-yl- phenoxy}-butyrique, procede pour sa preparation et composition pharmaceutique le contenant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAUGER, JACQUES

Inventor name: GOURVEST, JEAN-FRANEOIS

Inventor name: BROTO, PIERRE

Inventor name: BHATNAGAR, NEERJA

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071109

18D Application deemed to be withdrawn

Effective date: 20080519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20080520